Thiotriazolin Influence on Blood Pressure Changes in Patients with Myocardial Infarction and Concomitant Arterial Hypertension Who Underwent Remedial Treatment and Physical Rehabilitation


myocardial infarction

hypertensive disease

How to Cite

Prytuliak, O. M. (2015). Thiotriazolin Influence on Blood Pressure Changes in Patients with Myocardial Infarction and Concomitant Arterial Hypertension Who Underwent Remedial Treatment and Physical Rehabilitation. Galician Medical Journal, 22(4), 1-4. Retrieved from


The objective of the research was to study and investigate the efficiency of Thiotriazolin combined with antihypertensive drugs in connection with background therapy (BT) on the daily dynamics of blood pressure (BP) in comparison with the use of antihypertensive drugs only in connection with BT.

Results of the research: Positive dynamics in the reduction of the frequency of the disease subjective clinical signs manifestations in two research groups was observed (р<0.05). Significant decrease in pain syndrome and dyspnea was detected in patients with myocardial infarction (MI) and concomitant arterial hypertension (AH). The use of BT with ramipril and thiotriazolin ensured a gradual increase in the number of patients with the most favorable profile “diрper”. The inclusion of ramipril to BT or its combination with thiotriazolin resulted in a significant decrease in diastolic blood pressure (DBP) variability. Dynamics of systolic blood pressure (SBP) morning rise rate was analyzed. Morning rise rate (MRR) of systolic blood pressure significantly decreased in 3 months of investigation in patients treated with BT and ramipril or its combination with thiotriazolin.

Conclusions: due to combined treatment with ramipril and thiotriazolin in connection with BT a greater number of patients achieved BP target level and decreased BP morning rise indicators. 



Amosova EN. Arterial hypertension treatment – 2010: comments on the fundamental principles of the latter (2009) recommendations of the European Society of Cardiology and the European Society of Hypertension. Part II. Focus on combined antihypertensive therapy. Sertse i sudyny. 2010; 3: 17–28.

Dzyak GV, Vasilieva LI, Sapozhnichenko LV. [et al.] Evaluation of the thiotriazolin effectiveness according to the treadmill test in the complex treatment of patients with stable coronary heart disease. Novosti meditsiny i farmatsii. 2011; 13–14: 6–9.

Kovalenko VM, Kornatskyi VM. Implementation of the State program to combat hypertension in Ukraine. Ukr. kardiol. zhurnal. 2010; 6: 7-12.

Kovalenko VM, Kornatskyi VM. Regional medical and social problems of cardiovascular diseases. Dynamics and analysis. Kyiv. 2008; 238.

Mancia G, Grassi G. What changes we may expect in 2010 hypertension diagnosis and management: Insights from European update document. Curr. Vasc. Pharmacol. 2010; 8 (6): 788–791.

Parkhomenko OM, Kozhukhov SM, Irkin OI [et al.] New possibilitites of pharmacological effect on prognosis in patients who suffer from myocardial infarction with ST segment elevation and acute heart failure. Ukr. med. chasopys. 2010; 4 (78): 34-37.

Sirenko YuM, Radchenko HD, Martsovenko IM. Experience in treatment of patients with hypertension using domestic drugs. Ukr. kardiol. zhurnal. 2010; 1: 27-37.

Sirenko YuM, Radchenko HD, Mikheyeva KV, Rekovets OL. Comparative efficacy of thiotriazoline and meldonium in patients with stable angina of II-III functional class: results of a prospective open comparative randomized parallel studies. Novosti meditsiny i farmatsii. 2011; 17: 6–9.

Yena LM, Hrushovska VM. Hypertension and diastolic dysfunction in senile age: the impact of long-term combined antihypertensive and metabolic therapy. Sertse i sudyny. 2010; 2: 90–96.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.